SUPPLEMENTAL FIGURES AND TABLES from Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes

Autor: Jacobus Pfisterer, Sean C. Dowdy, Ellen L. Goode, Lynn C. Hartmann, Timothy Perren, Richard Kaplan, Mahesh Parmar, Andrew C. Embleton, Jeremy Chien, Ulrich Canzler, Alexander Burges, Willibald Schroeder, Klaus Baumann, Sven Mahner, Felix Hilpert, Andreas du Bois, Friedrich Kommoss, Viji Shridhar, Craig April, Matthew J. Maurer, Jian-Bing Fan, Shaun M. Riska, Chen Wang, Gottfried E. Konecny, Ann L. Oberg, Boris Winterhoff, Stefan Kommoss
Rok vydání: 2023
DOI: 10.1158/1078-0432.22466772.v1
Popis: Appendix 1: Additional Methods for Subtype Assignment Figure S1. Consistency check between published supervised classification vs. novel unsupervised clustering in TCGA Figure S2. Subclasses were computed by applying a consensus NMF clustering method which confirmed the presence of four stable clusters. Consensus matrices and sample correlation matrices are shown for k=2 to k=8 using the 1500 probe sets based on genes described by TCGA. Figure S3. Kaplan Meier analysis of progression free and overall survival for bevacizumab vs. standard treatment. Panel A: total study population. Panel B: patients at high risk for progression (suboptimally cytoreduced stage III and all stage IV patients) Supplemental Table 1. Results of progression-free survival restricted mean
Databáze: OpenAIRE